The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A meta-analysis of smoking status on clinical outcomes of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor.
Yoshikazu Hasegawa
No relevant relationships to disclose
Masahiko Ando
No relevant relationships to disclose
Makoto Maemondo
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim
Honoraria - AstraZeneca; Boehringer Ingelheim
Research Funding - Boehringer Ingelheim
Satomi Yamamoto
No relevant relationships to disclose
Shun-ichi Isa
No relevant relationships to disclose
Hideo Saka
Honoraria - Chugai Pharma; Lilly
Research Funding - AstraZeneca; Chugai Pharma; Lilly
Akihito Kubo
Honoraria - Chugai Pharma
Tomoya Kawaguchi
Honoraria - AstraZeneca; Chugai Pharma
Minoru Takada
No relevant relationships to disclose
Takayasu Kurata
Honoraria - AstraZeneca
Sai-Hong Ignatius Ou
No relevant relationships to disclose